- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT00192309
Phase II Study to Investigate the Kinetics of the Immune Response Generated by Influenza Virus Vaccine.
2012년 2월 13일 업데이트: MedImmune LLC
A Randomized, Open-Label, Placebo-Controlled Trial to Investigate the Kinetics of the Immune Responses Elicited by a Liquid Formulation of Influenza Virus Vaccine, Trivalent,Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Adults Aged 18 to <65 Years.
The primary objective of this study was to perform a variety of assays on blood, serum, nasal wash and cell samples obtained from healthy adult subjects for the purposes of developing assays for application in the further investigation of immune responses generated by influenza virus vaccine, trivalent, types A & B, live, cold-adapted (liquid formulation CAIV-T; Wyeth, Marietta, PA).
연구 개요
상세 설명
This was a randomized, open-label, placebo-controlled, outpatient study carried out in healthy adults 18 to < 65 years of age.
The study was designed to evaluate the kinetics of the immune responses generated by each of the study products in order to determine the best sampling time for future studies.
Subjects were randomized in a 1:1:1 ratio to receive a single dose of either CAIV-T, inactivated influenza virus vaccine (TIV), or placebo.
연구 유형
중재적
등록 (실제)
31
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Connecticut
-
Stamford, Connecticut, 미국, 06905
- David M. Radin, MD
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
공부할 수 있는 나이
18년 (성인, 고령자)
건강한 자원 봉사자를 받아들입니다
아니
연구 대상 성별
모두
설명
Inclusion Criteria:
- Subjects had to have been at least 18 years of age and less than 65 years of age at the time informed consent was obtained;
- Women of child-bearing potential had to use reliable methods of hormonal and/or nonhormonal contraception (which includes cervical cap, diaphragm, condoms with spermicide or IUD) during sexual intercourse throughout the entire study period; a negative urine pregnancy test (with detection limit of less than or equal to 25mIU/mL) no more than 24 hours prior to vaccine administration; and agreed to avoid pregnancy during participation in the study. A urine pregnancy test was also conducted at the completion of study participation. Females who were surgically sterile at time of enrollment were not required to undergo pregnancy testing.
- who were determined by medical history, physical examination and clinical judgement to be eligible for the study.
- who provided written informed consent after the nature of the study has been explained;
- who were available for one month duration of the trial (from enrollment to study completion);
- who could be reached by study staff for the post-vaccination contact [telephone, clinic or home visit].
Exclusion Criteria:
- who were perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
- with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids and intranasal steroids; or cytotoxic agents;
- who had an immunosuppressed or an immunocompromised individual living in the same household;
- who had a documented history of hypersensitivity to egg or egg protein or any other component of the study vaccine or placebo;
- who received any commercially-available or investigational injected influenza vaccine in the 6 months prior to enrollment, or a non-study influenza vaccine since enrollment;
- who previously received an intranasally administered influenza vaccine;
- who had any medical conditions that, in the opinion of the investigator, might interfere with interpretation of the study results;
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 방지
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 없음(오픈 라벨)
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Cold-adapted influenza vaccine (CAIVT)
A single intranasal dose of 10^7 fluorescent focus units.
|
Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains.
The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified.
Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
다른 이름들:
|
|
활성 비교기: Trivalent inactivated vaccine (TIV)
A single dose of commercially available Flushield was administered intramuscularly.
|
TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA.
Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
다른 이름들:
|
|
위약 비교기: Placebo
The 0.2 mL administered intranasally.
|
Placebo in this study consisted of physiological saline.
The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Kinetics of the hemagglutination inhibition antibody response to each vaccine strain
기간: Day 0-28
|
The geometric mean titers for each strain between Day 0 and 28 were examined.
|
Day 0-28
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Expression of IgA in nasal wash and saliva swab samples
기간: Days 0-28
|
Nasal wash and saliva swab IgA antibody titers were expressed as the ratio of specific to total IgA.
|
Days 0-28
|
|
Expression of B-cells in peripheral blood
기간: Days 0-28
|
The B-cell ELISPOT assays are designed to detect B-cells in the peripheral blood that are actively secreting influenza strain-specific IgG or IgA antibody.
|
Days 0-28
|
|
Number of CD3+ peripheral blood mononuclear cells secreting interferon gamma
기간: Days 0-28
|
The number of CD3+ peripheral blood mononuclear cells (PBMCs), i.e., T-cells, secreting IFN-γ prior to and after vaccination following in vitro stimulation of these cells using the IFN-γ ELISPOT assay.
|
Days 0-28
|
|
Number of subjects with local reactions
기간: Days 0-7
|
Local injection site reactions were collected from subjects in the TIV treatment group only.
|
Days 0-7
|
|
Number of subjects with systemic reactions
기간: Days 0-7
|
Each study subject collected prompted reactogenicity events on a diary card worksheet for 7 days (study days 0 - 6) following vaccination.
|
Days 0-7
|
|
Number of subjects with adverse events
기간: Days 0-7
|
An Adverse Event (or Adverse Experience, AE) was any untoward, undesired or unexpected clinical event in the form of signs, symptoms, disease or laboratory or physiological observations occurring (in a human being) in a temporal relationship to the use of a WLV product, regardless of causal relationship.
|
Days 0-7
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
스폰서
수사관
- 수석 연구원: Robert Walker, MD, MedImmune LLC
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작
2001년 9월 1일
기본 완료 (실제)
2001년 12월 1일
연구 완료 (실제)
2001년 12월 1일
연구 등록 날짜
최초 제출
2005년 9월 12일
QC 기준을 충족하는 최초 제출
2005년 9월 12일
처음 게시됨 (추정)
2005년 9월 19일
연구 기록 업데이트
마지막 업데이트 게시됨 (추정)
2012년 2월 14일
QC 기준을 충족하는 마지막 업데이트 제출
2012년 2월 13일
마지막으로 확인됨
2012년 2월 1일
추가 정보
이 연구와 관련된 용어
추가 관련 MeSH 약관
기타 연구 ID 번호
- D153 P004
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .